{
    "organizations": [],
    "uuid": "6e9d491de8381736be8d6bca0b55f6e8ac9b2629",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-redhill-biopharma-announces-final/brief-redhill-biopharma-announces-final-results-from-phase-ii-study-with-bekinda-for-ibs-d-idUSFWN1PB13C",
    "ord_in_thread": 0,
    "title": "BRIEF-Redhill Biopharma Announces Final Results From Phase II Study With Bekinda For IBS-D",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - Redhill Biopharma Ltd:\n* REDHILL BIOPHARMA ANNOUNCES FINAL RESULTS FROM PHASE II STUDY WITH BEKINDAÂ® FOR IBS-D\n* REDHILL BIOPHARMA - INDEPENDENT REVIEW & ANALYSIS OF FINAL RESULTS CONFIRMED THAT PHASE II STUDY WITH BEKINDA 12 MG SUCCESSFULLY MET PRIMARY ENDPOINT\n* REDHILL BIOPHARMA - PLANS TO MEET WITH FDA IN H1 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-16T21:11:00.000+02:00",
    "crawled": "2018-01-17T20:07:31.015+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "redhill",
        "biopharma",
        "ltd",
        "redhill",
        "biopharma",
        "announces",
        "final",
        "result",
        "phase",
        "ii",
        "study",
        "redhill",
        "biopharma",
        "independent",
        "review",
        "analysis",
        "final",
        "result",
        "confirmed",
        "phase",
        "ii",
        "study",
        "bekinda",
        "mg",
        "successfully",
        "met",
        "primary",
        "endpoint",
        "redhill",
        "biopharma",
        "plan",
        "meet",
        "fda",
        "h1",
        "discus",
        "design",
        "one",
        "two",
        "pivotal",
        "phase",
        "iii",
        "study",
        "bekinda",
        "mg",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}